Nature Communications | Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion

This study provides a novel paradigm for ex vivo expansion strategies in CAR-T cell therapy, suggesting that T cell exhaustion can be addressed through external signal programming rather than genetic modification, offering direct inspiration for optimizing cell manufacturing processes.

 

Literature Overview

This article, titled "Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion," published in Nature Communications, systematically explores the mechanisms and effects of using PLGA microparticles loaded with programmable DNA scaffolds (CAREp) to achieve sustainable ex vivo expansion of human CAR-T cells. This is achieved by precisely controlling the nanoscale organization of CD28 co-stimulatory signals and CAR antigen presentation.

Background Knowledge

1. The pain point in tumor immunotherapy addressed by this study is the limited expansion capacity of existing CAR-T cells during in vitro manufacturing and insufficient persistence after reinfusion, leading to poor efficacy against solid tumors.
2. The main bottleneck in current T cell expansion is that traditional CD3/CD28 magnetic beads or tumor cell stimulation often lead to premature differentiation, exhaustion, and telomere shortening, lacking long-term proliferation methods that maintain a memory phenotype.
3. The entry point of this study lies in the hypothesis that precisely controlling the stoichiometry and spatial organization of extracellular signals via synthetic materials can reprogram early T cell signaling pathways, activating genes related to DNA repair, telomere maintenance, and mitochondrial function, thereby achieving long-term optimization of cell fate without genetic editing.

 

 

Research Methods and Experiments

The authors constructed DNA scaffold PLGA microparticles (CAREp) surface-modified with EGFR antigen and CD28 agonistic antibodies, simulating an optimal co-stimulatory environment by adjusting the ratio of the two (e.g., 9:1). The study utilized CD8+ T cells from healthy donors transduced with CARs containing either 4-1BBζ or CD28ζ domains, subjected to multi-round pulsed stimulation experiments in vitro. Key evidence includes: the CAREp stimulation group achieved a cumulative expansion of up to 10^18-fold over 100 days, far exceeding traditional Dynabeads or tumor cell co-culture groups; flow cytometry showed that the CD62L+CD45RA+ memory progenitor population remained at a high proportion after multiple expansions; transcriptome sequencing revealed that differentiation pathways such as NFAT and NF-κB were suppressed, while telomerase activity and mitochondrial respiration capacity were significantly enhanced.

Key Conclusions and Perspectives

• It was discovered that CAREp reprograms T cell signaling through nanoscale ligand organization, achieving sustained ex vivo expansion for up to 100 days while maintaining CAR-T cell effector functions, with a cumulative expansion factor of 10^18-fold, providing a new pathway for large-scale production in subsequent cell therapies.
• It was confirmed that the precise ratio of CD28 co-stimulatory signals to CAR antigens (e.g., 9:1) is key to inducing memory progenitor enrichment and delaying T cell exhaustion, suggesting that optimizing the in vitro culture microenvironment is more effective than simply increasing stimulation intensity.
• The study reveals that CAREp stimulation can transiently activate telomerase and delay telomere shortening, while enhancing mitochondrial respiratory reserve capacity, indicating that external signal engineering can synchronize acute signaling with long-term metabolic homeostasis, which has important guiding significance for improving cell persistence in solid tumor treatment.
• Single-cell sequencing showed that CAREp induced a unique differentiation trajectory, shifting from a memory state to a persistent effector-like state (Cluster 6) rather than the traditional terminal differentiation pathway, providing molecular-level targets for designing novel immune cell expansion protocols.

Research Significance and Prospects

This discovery has profound implications for drug development, indicating that the bottleneck of CAR-T cell expansion can be overcome through biomaterial engineering without complex genetic editing, potentially reducing production costs and improving cell product quality. In terms of clinical monitoring, the study suggests focusing on cell product telomere length and mitochondrial function indicators to predict in vivo persistence after reinfusion. Furthermore, this strategy offers a new approach for disease modeling, utilizing programmable microparticles to simulate the complex immune microenvironment in vivo and study the fate determination mechanisms of T cells under chronic antigen stimulation.

 

 

Conclusion

Through innovative programmable microparticle technology, this study successfully broke through the physiological limits of ex vivo CAR-T cell expansion, achieving "reprogramming" of cell function without altering the genotype. This achievement not only solves the long-standing problem of insufficient cell persistence in tumor immunotherapy but also establishes a new standard for cell therapy preparation for related diseases. From laboratory to clinical translation, this strategy is expected to significantly improve the efficacy of CAR-T cells in solid tumor treatment by optimizing the extracellular signal environment to maintain the memory progenitor pool, thereby building a more robust immune defense system. This marks a new stage in cell therapy moving from pure genetic engineering to the integration of material and bioengineering, laying a solid foundation for the future development of more durable and safe immunotherapies.

 

Qinghe Zeng, Landon Flemming, Yuanzhou Chen, Tejal A Desai, and Xiao Huang. Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. Nature Communications.